#transformativescience

In the evolving landscape of biotechnology, Dr. Frederic Bard stands as a figure of innovation, leadership, and scientific courage. His profile featured in Business APAC charts the journey from rigorous academic research to founding Albatroz Therapeutics — a company focused on first-in-class antibody therapeutics for cancer and arthritis.

Bard’s research began with the discovery of the TANGO genes and moved through glycosylation-driven tissue remodeling. Today, he leads a biotech enterprise that seeks to disrupt both tumor metastasis and cartilage degradation. His leadership shows how science, vision and ethics can converge to create meaningful change.

Under his direction, the company pursues treatments that are potent yet minimise toxicity — a balance that many leaders struggle to achieve. His story offers professionals a powerful example: when you combine deep technical mastery with entrepreneurial grit, you can build solutions that matter.